Overview: Viral Subtype Markers TestIntroduction: The Viral Subtype Markers Test identifies viral subtypes to diagnose specific viral infections, helping guide treatment for symptoms like fever or respiratory issues. Affecting 1 in 100 people with viral infections, subtype identification poses diagnostic challenges due to diversity. Following 2023 Centers for Disease Control and Prevention (CDC) guidelines, it uses PCR/sequencing for high accuracy, supporting virology screening. This test is vital for diagnosis, treatment planning, and improving outcomes in infectious disease.
Other Names: Viral Subtyping Test, Viral Marker Assay.
FDA Status: FDA-approved test, meeting virology standards for diagnostic reliability.
Historical Milestone: Viral subtype testing began in the 1980s with research by Holland, who advanced sequencing. PCR advancements by Thermo Fisher improved detection, surpassing earlier serology methods.
Purpose: Identifies viral subtype identification to diagnose specific infections, guides antiviral therapy, and evaluates patients with fever, aiming to resolve infection.
Test Parameters: Viral subtype identification
Pretest Condition: Fresh swab or serum sample required. Collect whole blood or swab. Report history of viral exposure.
Specimen: Whole Blood (EDTA, 3-5 mL), Swab (sterile swab/transport medium, 1-2 swabs); Swab or 2 mL serum in sterile container. Transport in a biohazard container.
Sample Stability at Room Temperature: 4 hours
Sample Stability at Refrigeration: 24 hours
Sample Stability at Frozen: 1 month
Medical History: Document fever or respiratory issues. Include current medications or exposure history.
Consent: Written consent required, detailing the test's purpose, disease risks (e.g., pneumonia), and sample collection risks.
Procedural Considerations: Uses PCR/sequencing to identify subtypes, requiring labs with thermal cyclers. Results available in 3-5 days. Performed in labs with strict handling.
Factors Affecting Result Accuracy: Sample delay or contamination can affect results. Medications may not affect results but require correlation.
Clinical Significance: Specific subtype confirms infection, guiding therapy. Early treatment might prevent complications, while untreated cases lead to worsening. Negative results may require other tests.
Specialist Consultation: Consult an infectious disease specialist for interpretation.
Additional Supporting Tests: Viral culture, serology, or antigen test to confirm diagnosis.
Test Limitations: Specific to subtypes; correlation with clinical status needed. False negatives possible with low viral load.
References: CDC Guidelines, 2023; Journal of Virology, Holland JJ, 2022.
